I-Corps: SwiftVax - A Green Manufacturing Platform for Faster, Cheaper, and Scalable Vaccine Manufacturing

I-Corps：SwiftVax - 一个绿色制造平台，可实现更快、更便宜和可扩展的疫苗制造

• 批准号: 1158807
• 负责人: Karen McDonald
• 金额: $ 5万
• 依托单位: University of California-Davis
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-10-01 至 2013-03-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1158807&HistoricalAwards=false
• 关键词: Corps; SwiftVax; Green; Manufacturing; Platform

The proposed manufacturing platform is a technology that enables the use of nontransgenic tobacco plants as biofactories of vaccines, and takes advantage of 3 different biological systems working in synergy: (1) Agrobacterium tumefaciens for effective transfer of DNA that codes for the vaccine of interest; (2) Plant virus for increased vaccine yield; (3) Non-transgenic tobacco plants as hosts for vaccine synthesis. Using tobacco as vaccine biofactories, instead of traditional manufacturing processes, is potentially significant. Capital and operating costs can be significantly reduced, up to 90%, while vaccine development time is reduced from months to weeks. The proposed technology represents an emerging trend within the biotechnology industry. FDA is now willing to approve therapeutics manufactured in non-traditional production systems that are "biobetter". Biobetter means faster, more efficient, substantially cheaper, and greener; compared to traditional technologies. The proposing team has deep experience in this field, and recent developments in optimization approaches from the group, and others, have positioned this technology on the brink of commercialization and significant societal impact.Epidemics of recent emerging infectious diseases, such as the H1N1 pandemic, demand cost-efficient and scalable production technologies that can rapidly deliver effective therapeutics into the clinical setting. The mission of this proof-of-concept is to bring the rapid, scalable, and cost-efficient vaccine manufacturing capabilities of the technology platform outside of the research lab and closer to the market. This technology can impact diverse markets such as proteins for research use, as well as veterinary and human vaccines, and can improve the quality and affordability of animal and human health globally. Successful validation and commercialization of this manufacturing platform for recombinant proteins as reagents and/or diagnostics would demonstrate the production platform and open up new markets, which were not cost effective with previous biomanufacturing practices.

提出的生产平台是一种能够使用非转基因烟草植物作为疫苗生物工厂的技术，并利用协同作用的3种不同生物系统：（1）根癌土壤杆菌，用于有效转移编码目标疫苗的DNA;（2）植物病毒，用于提高疫苗产量;（3）非转基因烟草植物作为疫苗合成的宿主。使用烟草作为疫苗生物工厂，而不是传统的制造工艺，具有潜在的重要意义。资本和运营成本可以显著降低，最高可达90%，同时疫苗开发时间从数月缩短至数周。拟议的技术代表了生物技术行业的一个新兴趋势。FDA现在愿意批准在非传统生产系统中生产的“生物更好”的治疗药物。与传统技术相比，生物更好意味着更快，更高效，更便宜，更环保。 该项目团队在该领域拥有丰富的经验，并且该团队和其他人在优化方法方面的最新进展使该技术处于商业化和重大社会影响的边缘。最近出现的传染病流行，如H1N1大流行，需要具有成本效益和可扩展的生产技术，可以快速将有效的治疗药物提供给临床环境。这一概念验证的使命是将该技术平台的快速、可扩展和具有成本效益的疫苗制造能力带到研究实验室之外，并更接近市场。这项技术可以影响不同的市场，如研究用蛋白质，以及兽医和人类疫苗，并可以提高全球动物和人类健康的质量和可负担性。这种用于重组蛋白作为试剂和/或诊断剂的制造平台的成功验证和商业化将展示生产平台并开辟新市场，这在以前的生物制造实践中并不具有成本效益。